{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:53:11Z","timestamp":1790790791441,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00393-020-00928-7","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T12:03:53Z","timestamp":1605873833000},"page":"988-994","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Anifrolumab for the treatment of active systemic lupus erythematosus: a\u00a0meta-analysis of randomized controlled trials","Anifrolumab zur Behandlung des aktiven systemischen Lupus erythematodes: eine Metaanalyse randomisierter kontrollierter Studien"],"prefix":"10.1007","volume":"80","author":[{"given":"Y. H.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. G.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"928_CR1","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/j.0022-202X.2005.23889.x","volume":"125","author":"J Albrecht","year":"2005","unstructured":"Albrecht\u00a0J, Taylor\u00a0L, Berlin\u00a0JA et\u00a0al (2005) The CLASI (cutaneous lupus erythematosus disease area and severity index): an outcome instrument for cutaneous lupus erythematosus. J\u00a0Invest Dermatol 125:889\u2013894","journal-title":"J Invest Dermatol"},{"key":"928_CR2","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.4049\/jimmunol.1002795","volume":"192","author":"MK Crow","year":"2014","unstructured":"Crow\u00a0MK (2014) Type I interferon in the pathogenesis of lupus. J\u00a0Immunol 192:5459\u20135468","journal-title":"J Immunol"},{"key":"928_CR3","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1136\/annrheumdis-2018-214530","volume":"78","author":"M Dall\u2019era","year":"2019","unstructured":"Dall\u2019era\u00a0M, Bruce\u00a0IN, Gordon\u00a0C et\u00a0al (2019) Current challenges in the development of new treatments for lupus. Ann Rheum Dis 78:729\u2013735","journal-title":"Ann Rheum Dis"},{"key":"928_CR4","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(05)63833-0","volume":"350","author":"G Davey Smith","year":"1997","unstructured":"Davey Smith\u00a0G, Egger\u00a0M (1997) Meta-analyses of randomised controlled trials. Lancet 350:1182","journal-title":"Lancet"},{"key":"928_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/ar3433","volume":"13","author":"T D\u00f6rner","year":"2011","unstructured":"D\u00f6rner\u00a0T, Giesecke\u00a0C, Lipsky\u00a0PE (2011) Mechanisms of B cell autoimmunity in SLE. Arthritis Res Ther 13:243","journal-title":"Arthritis Res Ther"},{"key":"928_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger\u00a0M, Davey Smith\u00a0G, Schneider\u00a0M et al (1997) Bias in meta-analysis detected by a\u00a0simple, graphical test. BMJ 315:629\u2013634","journal-title":"BMJ"},{"key":"928_CR7","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.2147\/DDDT.S170969","volume":"13","author":"R Felten","year":"2019","unstructured":"Felten\u00a0R, Scher\u00a0F, Sagez\u00a0F et al (2019) Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date. Drug Des Devel Ther 13:1535\u20131543","journal-title":"Drug Des Devel Ther"},{"key":"928_CR8","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/art.39962","volume":"69","author":"R Furie","year":"2017","unstructured":"Furie\u00a0R, Khamashta\u00a0M, Merrill\u00a0JT et al (2017) Anifrolumab, an anti-interferon\u2011\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol 69:376\u2013386","journal-title":"Arthritis Rheumatol"},{"key":"928_CR9","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie\u00a0RA, Morand\u00a0EF, Bruce\u00a0IN et al (2019) Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a\u00a0randomised, controlled, phase 3 trial. Lancet Rheumatol 1:e208\u2013e219","journal-title":"Lancet Rheumatol"},{"key":"928_CR10","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/art.24698","volume":"61","author":"RA Furie","year":"2009","unstructured":"Furie\u00a0RA, Petri\u00a0MA, Wallace\u00a0DJ et al (2009) Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 61:1143\u20131151","journal-title":"Arthritis Rheum"},{"key":"928_CR11","doi-asserted-by":"publisher","DOI":"10.2217\/ijr.13.58","author":"Y Ghodke-Puranik","year":"2013","unstructured":"Ghodke-Puranik\u00a0Y, Niewold\u00a0TB (2013) Genetics of the type I interferon pathway in systemic lupus erythematosus. Int J Clin Rheumtol. https:\/\/doi.org\/10.2217\/ijr.13.58","journal-title":"Int J Clin Rheumtol"},{"key":"928_CR12","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins\u00a0JP, Thompson\u00a0SG (2002) Quantifying heterogeneity in a\u00a0meta-analysis. Stat Med 21:1539\u20131558","journal-title":"Stat Med"},{"key":"928_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4","author":"AR Jadad","year":"1996","unstructured":"Jadad\u00a0AR, Moore\u00a0RA, Carroll\u00a0D et\u00a0al (1996) Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. https:\/\/doi.org\/10.1016\/0197-2456(95)00134-4","journal-title":"Control Clin Trials"},{"key":"928_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1177\/0961203315627202","volume":"25","author":"YH Lee","year":"2016","unstructured":"Lee\u00a0YH, Choi\u00a0S, Ji\u00a0JD et al (2016) Overall and cause-specific mortality in systemic lupus erythematosus: an updated meta-analysis. Lupus 25:727\u2013734","journal-title":"Lupus"},{"key":"928_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4078\/jrd.2020.27.1.37","volume":"27","author":"YH Lee","year":"2020","unstructured":"Lee\u00a0YH, Song\u00a0GG (2020) Associations between circulating interleukin-17 levels and systemic lupus erythematosus and between interleukin-17 gene polymorphisms and disease susceptibility: a meta-analysis. J\u00a0Rheum Dis 27:37\u201344","journal-title":"J Rheum Dis"},{"key":"928_CR16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.4078\/jrd.2019.26.2.131","volume":"26","author":"YH Lee","year":"2019","unstructured":"Lee\u00a0YH, Song\u00a0GG (2019) Causal association between rheumatoid arthritis with the increased risk of type 2 diabetes: a\u00a0mendelian randomization analysis. J\u00a0Rheum Dis 26:131\u2013136","journal-title":"J Rheum Dis"},{"key":"928_CR17","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4078\/jrd.2019.26.4.257","volume":"26","author":"YH Lee","year":"2019","unstructured":"Lee\u00a0YH, Song\u00a0GG (2019) YKL-40 levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis. J\u00a0Rheum Dis 26:257\u2013263","journal-title":"J Rheum Dis"},{"key":"928_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher\u00a0D, Liberati\u00a0A, Tetzlaff\u00a0J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264\u2013269","journal-title":"Ann Intern Med"},{"key":"928_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand\u00a0EF, Furie\u00a0R, Tanaka\u00a0Y et\u00a0al (2020) Trial of anifrolumab in active systemic lupus erythematosus. N\u00a0Engl J Med 382:211\u2013221","journal-title":"N Engl J Med"},{"key":"928_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2020.1775928","author":"K Ohmura","year":"2020","unstructured":"Ohmura\u00a0K (2020) Which is the best SLE activity index for clinical trials? Mod Rheumatol. https:\/\/doi.org\/10.1080\/14397595.2020.1775928","journal-title":"Mod Rheumatol"},{"key":"928_CR21","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(00)04239-2","volume":"357","author":"G Ruiz-Irastorza","year":"2001","unstructured":"Ruiz-Irastorza\u00a0G, Khamashta\u00a0MA, Castellino\u00a0G et al (2001) Systemic lupus erythematosus. Lancet 357:1027\u20131032","journal-title":"Lancet"},{"key":"928_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4078\/jrd.2019.26.2.104","volume":"26","author":"GG Song","year":"2019","unstructured":"Song\u00a0GG, Lee\u00a0YH (2019) Causal association between bone mineral density and osteoarthritis: a mendelian randomization study. J\u00a0Rheum Dis 26:104\u2013110","journal-title":"J Rheum Dis"},{"key":"928_CR23","first-page":"S885","volume":"63","author":"D Wallace","year":"2011","unstructured":"Wallace\u00a0D, Strand\u00a0D, Furie\u00a0V et al (2011) Evaluation of treatment success in systemic lupus erythematosus clinical trials: development of the British Isles Lupus Assessment Group-based composite lupus assessment endpoint. Arthritis Rheum 63:S885\u2013S886","journal-title":"Arthritis Rheum"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00928-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-020-00928-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-020-00928-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T15:04:00Z","timestamp":1638889440000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-020-00928-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["928"],"URL":"https:\/\/doi.org\/10.1007\/s00393-020-00928-7","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,20]]},"assertion":[{"value":"30 October 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"Y.H.\u00a0Lee and G.G.\u00a0Song declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies performed were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}